Condition
Locally Advanced or Metastatic Urothelial Cell Carcinoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Terminated2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04636515Phase 2UnknownPrimary
A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma
NCT03123055Phase 1TerminatedPrimary
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
NCT02401542Phase 1TerminatedPrimary
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Showing all 3 trials